<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1066</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2008-4-3-45-49</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыря</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Comparative efficacy of conformal and conventional radiotherapy in organ conserving treatment of patients with invasive bladder cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Сравнительная эффективность конформной и конвенциальной лучевой терапии при органосохраняющем лечении больных инвазивным раком мочевого пузыря</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachev</surname><given-names>S. I.</given-names></name><name xml:lang="ru"><surname>Ткачев</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Medvedev</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Медведев</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Figurin</surname><given-names>K. M.</given-names></name><name xml:lang="ru"><surname>Фигурин</surname><given-names>К. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Enterprise N.N. Blokhin Russian Cancer Research Center of Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru">ГУ РОНЦ им. Н.Н. Блохина РАМН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2008-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2008</year></pub-date><volume>4</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>45</fpage><lpage>49</lpage><history><date date-type="received" iso-8601-date="2020-02-14"><day>14</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-02-14"><day>14</day><month>02</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1066">https://oncourology.abvpress.ru/oncur/article/view/1066</self-uri><abstract xml:lang="en"><p>Up to now radical cystectomy remains standard treatment modality for invasive transitional cell bladder cancer. Even reconstruction of bladder using other organs can not substitute patient's own organ. Data from numerous prospective single and multi-center trials which enrolled several thousands patients convincingly showed that survival after three-component combined modality treatment consisting of transurethral bladder resection, radiotherapy and chemotherapy is comparable to survival after cystectomy.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М.; 2005.</mixed-citation><mixed-citation xml:lang="ru">Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М.; 2005.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Матвеев Б.П., Фигурин К.М., Токтомушев А.Т. Результаты органосохраняющей терапии инвазивного рака мочевого пузыря. Урология 2002;3:3—5.</mixed-citation><mixed-citation xml:lang="ru">Матвеев Б.П., Фигурин К.М., Токтомушев А.Т. Результаты органосохраняющей терапии инвазивного рака мочевого пузыря. Урология 2002;3:3—5.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Dalbagni G., Genega E., Hasibe M. et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111—6.</mixed-citation><mixed-citation xml:lang="ru">Dalbagni G., Genega E., Hasibe M. et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111—6.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Ghoneim M.A. et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J Urol 1997;158: 393—9.</mixed-citation><mixed-citation xml:lang="ru">Ghoneim M.A. et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J Urol 1997;158: 393—9.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Lebret T., Herve J.M., Yonneau L. et al. Study of survival after cystectomy for bladder cancer. Report of 504 cases. Prog Urol 2000;10(4):553—60.</mixed-citation><mixed-citation xml:lang="ru">Lebret T., Herve J.M., Yonneau L. et al. Study of survival after cystectomy for bladder cancer. Report of 504 cases. Prog Urol 2000;10(4):553—60.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Stein J.P. et al. Radical cystectomy in invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19(3):666—75.</mixed-citation><mixed-citation xml:lang="ru">Stein J.P. et al. Radical cystectomy in invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19(3):666—75.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Michaelson D., Zietman A. Invasive bladder cancer: The role of bladder preserving therapy. ASCO 2003; p. 457—65.</mixed-citation><mixed-citation xml:lang="ru">Michaelson D., Zietman A. Invasive bladder cancer: The role of bladder preserving therapy. ASCO 2003; p. 457—65.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Rodel C., Weiss C., Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. Jpn J Clin Oncol 2006;24(35):5536—44.</mixed-citation><mixed-citation xml:lang="ru">Rodel C., Weiss C., Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. Jpn J Clin Oncol 2006;24(35):5536—44.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Matos T., Cufer T., Cervek J. et al. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys 2000;46(2):403—9.</mixed-citation><mixed-citation xml:lang="ru">Matos T., Cufer T., Cervek J. et al. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys 2000;46(2):403—9.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Ярмоненко С.П., Вайнсон А.А. Радиобиология человека и животных. М.; 2004.</mixed-citation><mixed-citation xml:lang="ru">Ярмоненко С.П., Вайнсон А.А. Радиобиология человека и животных. М.; 2004.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Саллум С.Ж. Органосохраняющее лечение рака мочевого пузыря T2N0M0. Автореф. дис. … канд. мед. наук. М.; 2005.</mixed-citation><mixed-citation xml:lang="ru">Саллум С.Ж. Органосохраняющее лечение рака мочевого пузыря T2N0M0. Автореф. дис. … канд. мед. наук. М.; 2005.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Shipley W.U., Kaufman D.S., Zehr E. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62—8.</mixed-citation><mixed-citation xml:lang="ru">Shipley W.U., Kaufman D.S., Zehr E. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62—8.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
